Immune-related adverse events of checkpoint inhibitors
M Ramos-Casals, JR Brahmer, MK Callahan… - Nature reviews Disease …, 2020 - nature.com
Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
Clinical and translational attributes of immune-related adverse events
KPM Suijkerbuijk, MJM van Eijs, F van Wijk… - Nature Cancer, 2024 - nature.com
With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many
cancers, managing their immune-related adverse events (irAEs) has become an important …
cancers, managing their immune-related adverse events (irAEs) has become an important …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) …
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …
therapy may vary substantially in their clinical presentation, including natural history …
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level …
Background A variety of dermatoses have been reported in the growing number of patients
treated with immune-checkpoint inhibitors (ICIs), but the current understanding of cutaneous …
treated with immune-checkpoint inhibitors (ICIs), but the current understanding of cutaneous …
Association between immune-related adverse event timing and treatment outcomes
D Hsiehchen, AR Naqash, M Espinoza… - …, 2022 - Taylor & Francis
The timing of immune-related adverse events (irAE) associated with immune checkpoint
inhibitors (ICI) is highly variable. Although the development of irAE has been associated with …
inhibitors (ICI) is highly variable. Although the development of irAE has been associated with …
Emerging management approach for the adverse events of immunotherapy of cancer
Immunotherapy, which stimulates the body's immune system, has received a considerable
amount of press in recent years because of its powerful benefits. Cancer immunotherapy …
amount of press in recent years because of its powerful benefits. Cancer immunotherapy …
[HTML][HTML] Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level …
Background Immune-related adverse events (irAEs) are a serious side effect of immune
checkpoint inhibitor (ICI) therapy for patients with advanced cancer. Currently, predisposing …
checkpoint inhibitor (ICI) therapy for patients with advanced cancer. Currently, predisposing …
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
Immune checkpoint inhibitors (ICIs) have minimal therapeutic effect in hormone receptor-
positive (HR+) breast cancer. We present final overall survival (OS) results (n= 88) from a …
positive (HR+) breast cancer. We present final overall survival (OS) results (n= 88) from a …
Advances in knowledge and management of immune-related adverse events in cancer immunotherapy
TA Olsen, TZ Zhuang, S Caulfield, DJ Martini… - Frontiers in …, 2022 - frontiersin.org
Immune-oncologic (IO) therapy has revolutionized the treatment and management of
oncologic disease. Immunotherapy functions by enhancing the host immune-systems ability …
oncologic disease. Immunotherapy functions by enhancing the host immune-systems ability …
Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
In light of positive efficacy and safety findings from the IMbrave150 trial of atezolizumab plus
bevacizumab, this novel combination has become the preferred first-line standard of care for …
bevacizumab, this novel combination has become the preferred first-line standard of care for …